Atrial Fibrillation (AF) is the most prevalent cardiac arrhythmia, affecting five million patients in the Western World. It is one of the leading causes of stroke and short-term hospitalizations with over 500,000 new cases diagnosed annually. In 2005, CryoCath's Arctic Front® received the CE Mark for all countries in the European Union.
Keep up to date on CryoCath
Sign up to receive news and information on CryoCath clinical trials, product launches and more.
2008
